FIELD: pharmaceutics.
SUBSTANCE: present invention relates to a novel quinazolinone derivative of formula 1, having PI3K inhibitor properties. Hematologic malignant tumor is leukemia or lymphoma. Hepatic disease is selected from a group consisting of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hepatic steatosis, hepatocirrhosis, hepatitis, hepatic adenoma, hypersensitivity to insulin and liver cancer. In formula 1
X is halogen or -CH3; and Y is C3-4 cycloalkyl.
EFFECT: compound can be used for preventing or treating hematological malignant tumor, liver disease or autoimmune disease.
4 cl, 9 dwg, 3 tbl, 6 ex
Authors
Dates
2019-10-14—Published
2017-07-13—Filed